MAP Pharmaceuticals, Inc.

• About Us 
  • Message from the CEO
  • Management Team
  • Board of Directors
  • Partnering
  • Contact Us
• Product Pipeline 
  • Pediatric Asthma Therapy
  • Inhaled Migraine Therapy
  • Asthma/COPD Therapy
  • Inhaled Diabetes Therapy
• Investor Relations 
  • IR Home
  • Press Releases
  • Calendar of Events
  • Corporate Governance
  • Management
  • Board of Directors
  • Committee Composition
  • Annual Reports
  • SEC Filings
  • Stock Information
  • Analyst Coverage
  • Contact Us
• Science & Technology 
• Publications 
  • Asthma
  • Migraine
  • Aerosol Science and Technology

Investor Relations

Print page     Email page

Investor Relations

Recent Releases

Jul 23, 2008
MAP Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development and Medical Affairs

Jul 16, 2008
MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion

Jul 14, 2008
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine

View all releases »

Stock Information

NASD:MAPP $9.20	+ 0.10
Jul 23, 2008	4:10 PM ET

Quotes delayed at least 20 minutes.
Information provided by TurboFeed.